This study retrospectively analyzed ten pediatric patients with HOX-driven AML who received revumenib maintenance after HSCT at a single-center. The median age was 10 years (range: 1-18). 80% (8/10) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback